Raymond James Financial reissued their buy rating on shares of Cooper Companies (NYSE:COO) in a research note released on Monday. Raymond James Financial currently has a $265.00 price target on the medical device company’s stock.
A number of other brokerages have also recently issued reports on COO. Robert W. Baird restated a buy rating and issued a $273.00 target price (up from $267.00) on shares of Cooper Companies in a report on Tuesday, September 12th. Zacks Investment Research upgraded Cooper Companies from a hold rating to a buy rating and set a $277.00 target price on the stock in a report on Tuesday, August 29th. Jefferies Group set a $250.00 target price on Cooper Companies and gave the stock a buy rating in a report on Thursday, August 17th. Oppenheimer restated a hold rating and issued a $250.00 target price on shares of Cooper Companies in a report on Tuesday, September 12th. Finally, Cleveland Research restated a buy rating on shares of Cooper Companies in a report on Tuesday, August 22nd. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Cooper Companies presently has a consensus rating of Buy and a consensus price target of $260.70.
Cooper Companies (NYSE COO) opened at $238.80 on Monday. The company has a quick ratio of 1.29, a current ratio of 2.51 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $11,350.84, a price-to-earnings ratio of 24.80, a P/E/G ratio of 1.94 and a beta of 0.54. Cooper Companies has a 1-year low of $165.98 and a 1-year high of $256.39.
In other news, Director Gary S. Petersmeyer sold 3,977 shares of Cooper Companies stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $244.94, for a total transaction of $974,126.38. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.60% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Janus Henderson Group PLC boosted its position in Cooper Companies by 558.5% during the second quarter. Janus Henderson Group PLC now owns 2,175,791 shares of the medical device company’s stock valued at $520,937,000 after purchasing an additional 1,845,368 shares during the last quarter. Pioneer Investment Management Inc. boosted its position in Cooper Companies by 136.6% during the second quarter. Pioneer Investment Management Inc. now owns 1,226,250 shares of the medical device company’s stock valued at $293,589,000 after purchasing an additional 708,028 shares during the last quarter. Koch Industries Inc. acquired a new stake in Cooper Companies during the second quarter valued at $312,000. Voya Investment Management LLC boosted its position in Cooper Companies by 973.4% during the second quarter. Voya Investment Management LLC now owns 329,015 shares of the medical device company’s stock valued at $78,773,000 after purchasing an additional 298,363 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Cooper Companies during the second quarter valued at $71,050,000. 96.79% of the stock is owned by hedge funds and other institutional investors.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.